The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
Abstract
PURPOSE: To determine the long-term clinical course of patients with metastatic breast cancer (MBC) who achieved a complete remission with doxorubicin-alkylating agent-containing combination chemotherapy programs. PATIENTS AND METHODS: To assess the long-term prognosis of MBC, we reviewed our experience with 1,581 patients treated on consecutive doxorubicin and alkylating agent-containing front-line treatment protocols between 1973 and 1982. Treatment was administered for a maximum duration of 2 years. Characteristics of long-term survivors were evaluated, and hazard rates for progression were calculated. RESULTS: From this group, 263 (16.6%) achieved complete responses (CR) and 49 (3.1%) remained in CR for more than 5 years. After a median duration of 191 months, 26 patients remain in first CR, four patients died in CR at times ranging from 118 to 234 months, 18 patients died of breast cancer, and one is alive with metastatic disease. Compared with the overall CR and total patient populations, the long-term CR group had more premenopausal patients, a younger median age, a lower tumor burden, and better performance status. The hazard function shows a substantial drop in risk of progression after approximately 3 years from initiation of therapy. Ten long-term CR patients developed second primary cancers: breast (3), ovary (2), pancreas (1), endometrium (1), colon (1), head and neck (1), and lung (1). CONCLUSION: Most patients with MBC treated with systemic therapies have only temporary responses to treatment, but some patients continue in CR following initial treatment. These data show that a small percentage of patients achieve long-term remissions with standard chemotherapy regimens. Remission consolidation strategies are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sapisochin, E. (1962) · PubMed · Cited by 908
Assessment of response to therapy in advanced breast cancer
Hayward, J. L., Carbone, P. P., Heusen, J. C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.42 · Cited by 705
Peters, W. P., Shpall, E. J., Jones, R. B., Olsen, G. A., Bast, R. C., Gockerman, J. P., & Moore, J. O. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.9.1368 · Cited by 374
Natural History of Untreated Breast Cancer (1805-1933)
Bloom, H. J. G., Richardson, W. W., & Harries, E. J. (1962) · BMJ · doi:10.1136/bmj.2.5299.213 · Cited by 255
FAILURE OF CHEMOTHERAPY TO PROLONG SURVIVAL IN A GROUP OF PATIENTS WITH METASTATIC BREAST CANCER
Powles, T. J., Smith, I. E., Ford, H. T., et al. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91066-1 · Cited by 128
Cited by
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
“(%) 18 (8) 8 (3) 11 (8) 6 (4) 7 (8) 2 (2)”
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Harbeck, N., & Gnant, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,280
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,135
Self-citationRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Hortobagyi, G. N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391407 · Cited by 781
Self-citationExtending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Stadtmauer, E. A., O'Neill, A., Goldstein, L. J., Crilley, P. A., Mangan, K. F., Ingle, J. N., Brodsky, I., Martino, S., Lazarus, H. M., Erban, J. K., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004133421501 · Cited by 460
Drug Combinations in Breast Cancer Therapy
Fisusi, F. A., & Akala, E. O. (2019) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666190122111224 · Cited by 449
Pagani, O., Senkus, E., Wood, W., Colleoni, M., Cufer, T., Kyriakides, S., Costa, A., Winer, E. P., Cardoso, F., & on behalf of the ESO-MBC Task Force (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq029 · Cited by 422
Nabholtz, J.-M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., Pienkowski, T., Zaluski, J., Pinter, T., Krzakowski, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.040 · Cited by 384
André, F., & Zielinski, C. C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds195 · Cited by 329
Jassem, J., Pieńkowski, T., Płuzańska, A., Jelic, S., Gorbunova, V., Mrsic-Krmpotic, Z., Berzins, J., Nagykalnai, T., Wigler, N., Renard, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1707 · Cited by 308
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Bonotto, M., Gerratana, L., Poletto, E., Driol, P., Giangreco, M., Russo, S., Minisini, A. M., Andreetta, C., Mansutti, M., Pisa, F. E., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0002 · Cited by 295
Nicolini, A., Carpi, A., & Rossi, G. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.07.002 · Cited by 279
The oligometastatic state—separating truth from wishful thinking
Palma, D. A., Salama, J. K., Lo, S. S., Senan, S., Treasure, T., Govindan, R., & Weichselbaum, R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.96 · Cited by 277
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Gobbini, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., Dalenc, F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.015 · Cited by 276
Ibrahim, N. K., Samuels, B., Page, R., Doval, D., Patel, K. M., Rao, S. C., Nair, M. K., Bhar, P., Desai, N., & Hortobagyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.013 · Cited by 267
Self-citationMechanism of action of anti-HER2 monoclonal antibodies
Baselga, J., & Albanell, J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s35 · Cited by 265
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259
Pivot, X., Spano, J. P., Espie, M., Cottu, P., Jouannaud, C., Pottier, V., Moreau, L., Extra, J. M., Lortholary, A., Rivera, P., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.009 · Cited by 70
Andreopoulou, E., & Sparano, J. A. (2013) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0097-1 · Cited by 65
Metadata
- Authors
- Greenberg, P. A., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., & Buzdar, A. U.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-08
- Volume
- 14
- Issue
- 8
- Pages
- 2197-2205
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2176579253
- Cited by
- 738
- References
- 5
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.